Status:
COMPLETED
Improving Prostate Lesion Classification and Development of a PI-RADS 3 Classifier
Lead Sponsor:
Paracelsus Medical University
Conditions:
Prostate Cancer
Eligibility:
MALE
18-90 years
Brief Summary
The investigators propose an AI methodology combining machine learning, histological results and expert image interpretation for the development of a PI-RADS 3 classifier.
Detailed Description
Prostate cancer is the most common carcinoma in male patients in Western industrialized countries. Multiparametric prostate MRI (mpMRI) can select patients who may be potential candidates for biopsy. ...
Eligibility Criteria
Inclusion
- Only patients with a clinical indication for mp prostate MRI will be included in this prospective study.
- No allergies to GBCA
Exclusion
- 1\. Contraindications for MRI
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 24 2023
Estimated Enrollment :
173 Patients enrolled
Trial Details
Trial ID
NCT06116344
Start Date
January 1 2018
End Date
August 24 2023
Last Update
November 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiology and Nuclear Medicine, Klinikum Nuernberg, Paracelsus Medical University, Germany
Nuremberg, Germany